IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Rating of "Moderate Buy" by Brokerages

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has received an average rating of "Moderate Buy" from the nineteen analysts that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $256.50.

Several equities analysts recently commented on IQV shares. The Goldman Sachs Group decreased their price target on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Morgan Stanley lowered their target price on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft dropped their price objective on IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Finally, StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in IQV. FMR LLC grew its position in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after buying an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in IQVIA in the third quarter valued at approximately $147,683,000. 1832 Asset Management L.P. increased its position in IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company's stock valued at $96,487,000 after purchasing an additional 376,595 shares during the period. Renaissance Technologies LLC bought a new position in IQVIA during the 2nd quarter worth approximately $70,610,000. Finally, Impax Asset Management Group plc lifted its position in shares of IQVIA by 19.3% in the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company's stock worth $344,998,000 after purchasing an additional 264,555 shares during the period. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

IQV traded up $2.70 during trading on Friday, hitting $202.63. The stock had a trading volume of 1,388,125 shares, compared to its average volume of 2,002,141. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a 50 day moving average price of $215.18 and a 200-day moving average price of $225.14. IQVIA has a one year low of $187.62 and a one year high of $261.73. The firm has a market cap of $36.78 billion, a price-to-earnings ratio of 26.59, a P/E/G ratio of 2.09 and a beta of 1.49.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.